INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.130
-0.010 (-0.88%)
At close: Mar 31, 2026, 4:00 PM EDT
1.120
-0.010 (-0.88%)
After-hours: Mar 31, 2026, 7:28 PM EDT

Revenue by Segment

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Pharmaceuticals
50.00K14.00K155.00K374.00K181.00K
Pharmaceuticals Growth
257.14%-90.97%-58.56%106.63%1545.45%
Total
50.00K14.00K155.00K374.00K181.00K
Total Growth
257.14%-90.97%-58.56%106.63%1545.45%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
United States
50.00K14.00K155.00K374.00K181.00K
United States Growth
257.14%-90.97%-58.56%106.63%1545.45%
Total
50.00K14.00K155.00K374.00K181.00K
Total Growth
257.14%-90.97%-58.56%106.63%1545.45%
Source: S&P Global Market Intelligence.